Modality
Nanobody
MOA
BiTE
Target
GLP-1R
Pathway
Wnt
PV
Development Pipeline
Preclinical
Feb 2017
→ Jun 2030
PreclinicalCurrent
NCT04157940
1,779 pts·PV
2017-02→2030-06·Terminated
1,779 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-09-286mo agoPDUFA· PV
2030-06-224.2y awayInterim· PV
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Preclinical
Termina…
Catalysts
PDUFA
2025-09-28 · 6mo ago
PV
Interim
2030-06-22 · 4.2y away
PV
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04157940 | Preclinical | PV | Terminated | 1779 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 |